Supplementary Material


Diagrama, Esquemático

Descripción generada automáticamente

Mann-Whitney:

W = 7371, *P* = 0.6675 W = 7270, *P* = 0.8093

**Figure S1.** Comparison of centile distributions between the two scanners used in the present sample.



**Figure S2**. Histograms illustrating the distributions of symptom (SANS, SAPS) and functioning (GAF) scores. Each histogram represents the frequency distribution of scores, with symptoms showing an exponential decay and functioning displaying an increasing trend. The data highlight the skewness typically observed in clinical assessments of symptoms and functioning.

Gráfico, Gráfico de dispersión

Descripción generada automáticamente

**Figure S3**. **a)** Averaged regional GMV centiles at baseline, differentiating between schizophrenia and other schizophrenia spectrum disorders (SSDs). **b)** Correlation matrix of GMV centiles, averaged within each diagnostic group across 82 brain regions. Each point represents a brain region. **c)** Boxplot comparing total GMV centiles at baseline between patients in each diagnostic group for both cortical and subcortical GMV. Each point represents an individual.

A screenshot of a computer screen

AI-generated content may be incorrect.

**Figure S4.** Effect of cortical and subcortical regional centiles at FEP baseline on SANS, SAPS and GAF total scores over a 10-year follow-up. Statistically significant values (*P*< .05, FDR-corrected) are represented by coloured regions, while non-significant regions are shown in white.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table S1. Demographic, clinical and functional measures | | | | | | | | | | | | | | | | | | |
|  | **Baseline** | | | | **1-year**  **follow-up** | | | | | **3-year**  **follow-up** | | | | | **10-year\***  **follow-up** | | | |
|  | Symptoms (n=241) | Functioning (n=244) | | Symptoms (n=233) | | | Functioning (n=236) | | Symptoms (n=208) | | | Functioning (n=222) | | Symptoms (n=106) | | | Functioning (n=85) | |
| Age, mean years (SD) | 28.75 (7.13) | | 30.58 (9.14) | | |  | |  | | |  | |  | | |  | |  |
| Sex, *n* (%) |  | | | |  | | | | |  | | | | |  | | | |
| Male | 158 (66%) | | 139 (57%) | | |  | |  | | |  | |  | | |  | |  |
| Female | 83 (34%) | | 105 (43%) | | |  | |  | | |  | |  | | |  | |  |
| Education, mean years (SD) | 10.27 (3.28) | | 10.40 (3.36) | | |  | |  | | |  | |  | | |  | |  |
| Family history of psychosis, *n* (%) | 55 (23%) | | 60 (25%) | | |  | |  | | |  | |  | | |  | |  |
| Low socioeconomic status, *n* (%) | 119 (49%) | | 116 (48%) | | |  | |  | | |  | |  | | |  | |  |
| dup, mean months (SD) | 11.42 (18.80) | | 10.43 (24.59) | | |  | |  | | |  | |  | | |  | |  |
| Antipsychotic dose, CPZ-eq, mean (SD), mg | 0 | | 0 | | | 293.13  (257.35) | | 255.99 (226.65) | | | 304.30  (269.50) | | 252.13 (229.86) | | | 422.29 (362.17) | | 341.64 (245.05) |
| Diagnosis, *n* (%) |  | | | |  | | | | |  | | | | |  | | | |
| Schizophrenia | 138 (57%) | | 111 (46%) | | |  | |  | | |  | |  | | |  | |  |
| Schizophreniform disorder | 81 (34%) | | 75 (31%) | | |  | |  | | |  | |  | | |  | |  |
| Schizoaffective disorder | 0 (0%) | | 3 (1%) | | |  | |  | | |  | |  | | |  | |  |
| Brief psychotic disorder | 0 (0%) | | 37 (15%) | | |  | |  | | |  | |  | | |  | |  |
| Schizotypal personality | 0 (0%) | | 0 (0%) | | |  | |  | | |  | |  | | |  | |  |
| Unspecified psychosis | 22 (9%) | | 18 (7%) | | |  | |  | | |  | |  | | |  | |  |
| Longitudinal assessments, median (min, max) | 3 (2, 4) | | 3 (2, 4) | | |  | |  | | |  | |  | | |  | |  |
| Assessments taken at years, median (min, max) | 0 (0, 0) | | 0 (0, 0) | | | 1 (1, 1) | | 1 (1, 1) | | | 3 (3, 3) | | 3 (3, 3) | | | 10.23 (8.31, 15.33) | | 9.96 (8.31, 10.97) |
| SANS total score, mean (SD) | 1.08 (1.24) | |  | | | 0.97 (1.17) | |  | | | 0.87 (1.26) | |  | | | 1.16 (1.29) | |  |
| Affective flattening | 1.11 (1.44) | |  | | | 0.95 (1.31) | |  | | | 0.90 (1.37) | |  | | | 1.22 (1.41) | |  |
| Alogia | 0.82 (1.41) | |  | | | 0.64 (1.15) | |  | | | 0.66 (1.25) | |  | | | 0.89 (1.37) | |  |
| Anhedonia | 1.40 (1.74) | |  | | | 1.22 (1.59) | |  | | | 1.00 (1.59) | |  | | | 1.44 (1.74) | |  |
| Inattention | 2.00 (1.92) | |  | | | 0.41 (1.10) | |  | | | 0.49 (1.20) | |  | | | 0.46 (1.00) | |  |
| Avolition | 0.98 (1.61) | |  | | | 1.05 (1.49) | |  | | | 0.93 (1.50) | |  | | | 1.08 (1.49) | |  |
| SAPS total score, mean (SD) | 3.20 (0.83) | |  | | | 0.29 (0.66) | |  | | | 0.32 (0.72) | |  | | | 0.38 (0.77) | |  |
| Bizarre behaviour | 4.20 (1.37) | |  | | | 0.27 (0.91) | |  | | | 0.27 (0.89) | |  | | | 0.27 (0.83) | |  |
| Delusions | 4.88 (0.44) | |  | | | 0.57 (1.34) | |  | | | 0.58 (1.29) | |  | | | 0.66 (1.24) | |  |
| Formal thought disorder | 1.11 (1.76) | |  | | | 0.06 (0.38) | |  | | | 0.08 (0.47) | |  | | | 0.20 (0.74) | |  |
| Hallucinations | 2.62 (2.30) | |  | | | 0.27 (1.00) | |  | | | 0.34 (1.09) | |  | | | 0.39 (1.10) | |  |
| GAF score, mean (SD) |  | | 54.89 (31.83) | | |  | | 80.28 (19.92) | | |  | | 80.82 (21.16) | | |  | | 82.80 (17.39) |
| DUP: Duration of Untreated Psychosis; CPZ-eq: Chlorpromazine equivalent doses; SANS: Scale for the Assessment of Negative Symptoms; SAPS: Scale for the Assessment of Positive Symptoms; GAF: Global Assessment of Functioning  \*For logistical reasons, last follow-ups occurred within an 8 to 15-year range | | | | | | | | | | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | Table S2. Statistical comparison between the final sample and the dropout group at baseline | | | | | | | | | | | | | | | | | | | | |
|  | | | |  |  | Symptoms | | | | | | | | |  | | | | Functioning | | | | |
|  | | | | **mean** | | | | ***t*** | | ***W*** | |  | | ***P (FDR)*** | **mean** | | | | | ***t*** | ***W*** | | ***P (FDR)*** |
|  | | | | Final sample (n=241) | | | Dropout group (n=111) |  | |  | |  | |  | Final sample (n=244) | | | Dropout group (n=108) | |  |  | |  |
| Total cortical GMV centile | | | | 0.36 | | | 0.41 | 1.62 | |  | |  | | .242 | 0.36 | | | 0.40 | | 1.06 |  | | .418 |
| Total subcortical GMV centile | | | | 0.42 | | | 0.49 | 2.23 | 2.23 | | .115 | | | | | | 0.43 | | 0.46 | 0.73 |  | .549 | |
| SANS | | | | 1.08 | | | 1.47 |  | 2951 | | | | .485 | | |  | | |  |  |  | |  |
| SAPS | | | | 3.20 | | | 3.07 |  | 2293 | | | | .418 | | |  | | |  |  |  | |  |
| GAF | | | |  | | |  |  |  | | | |  | | | 54.89 | | | 58.79 |  | 2999 | | .742 |
| Age of onset | | | | 28.74 | | | 32.69 |  | 15543 | | | | .095 | | | 30.52 | | | 28.57 |  | 11776 | | .242 |
| Sex, male | | | | 158 | | | 56 |  | χ2 = 6.66 | | | | .095 | | | 139 | | | 75 |  | χ2 = 4.38 | | .118 |
| GMV: Grey Matter Volume; SANS: Scale for the Assessment of Negative Symptoms; SAPS: Scale for the Assessment of Positive Symptoms; GAF: Global Assessment of Functioning | | | | | | | | | | | | | | | | | | | | | | | |